CD276 and glioma: Using antibody–drug conjugates to ablate CD276 + glioma cells simultaneously impaired tumor vescular [262], indicating a novel insight on the combination of anti-CD276 with anti-angiogenesis, which was supported when CD276 was confirmed to positively be related with VEGFA and MMP2 [267].